ClinicalTrials.gg
Status unknownNCT05478356AVOUpdated Jul 28, 2022

The Effects of Low-dose Atropine and Orthokeratology in Pediatric Myopia Control

An interventional study of low-dose atropine eye drops and orthokeratology in Myopia, sponsored by Evidence Based Cataract Study Group. Status unknown at 2 sites in China. Open to participants aged 8 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-28.

Sponsored by Evidence Based Cataract Study Group · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
8 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 222 studies in Myopia with a site in China — 80 open to participants now, 102 under way, 4 of them phase 3. Myopia · China.

Planned enrollment
105th of 155
100 · median 150
Started
2022
with 25 others
No phase
136 of 222
53 open now
Registered
80th of 222
by date

Among the 222 studies in Myopia with a site in China, this one is the 105th largest by planned enrollment of the 155 interventional ones that give a count, is one of 26 that started in 2022, is one of 136 with no phase, and was the 80th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

80 of the 222 studies in Myopia with a site in China are open now. Recruiting first, the newest first:

75 more — sign in →

All 80 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 8 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 222 studies in Myopia with a site in China, or all of them as a file.
02

Study summary

Both orthokeratology and atropine eye drops are effective methods for myopia control, but few studies have compared them all together simultaneously. Therefore, the primary aim of the present study was to compare the effect of orthokeratology versus low-dose (0.01% and 0.02%) atropine on the control of myopia progression.

03

Conditions studied

  • Myopia

Browse trials for

04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Best corrected visual acuity less then 0.00 log MAR (minimum angle of resolution) units Cycloplegic SER of - 1.0 D or less in both eyes. An inter-eye cycloplegic SER difference of 1.00 D or more.

Exclusion criteria

Exclusion Criteria:

Children with cycloplegic cylinder refraction of more than + 1.00 D or less than - 1.00 D.

History of binocular vision problems, including strabismus. History of known ocular disorders, including media opacities, macular dysgenesis, optic nerve hypoplasia, perinatal brain injury, buphthalmos, and retinopathy of prematurity.

History of medication use that might have affected the refractive results. Systemic or developmental problems that might have hindered refractive development.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    orthokeratology group

    Device: orthokeratology

  • Active comparator
    low-dose atropine group

    Drug: low-dose atropine eye drops

Interventions

  • DrugAtropineStudies of AtropineAtropine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    low-dose atropine eye drops

  • Deviceorthokeratology

    orthokeratology, ortho-K lenses

06

What researchers measure

Primary outcomes

  1. Progression of myopia

    The change of myopia (Ds)

    Time frame: 1 year

  2. Progression of axial length

    The change of axial length (mm)

    Time frame: 1 year

07

Study locations

2 of 2 sites recruiting
  • Visionly Eye Hospital
    Beijing, Beijing 100038, China
    Recruiting
  • Parkway Hospital
    Shanghai, Shanghai 200001, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2022; primary completion for Aug 2023, 12 months later.

Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 12 months is below that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2022
First posted
Jul 28, 2022
StartEst.
Aug 1, 2022
Primary completionEst.
Aug 31, 2023
CompletionEst.
Aug 31, 2023
Last update
Jul 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05478356
Lead sponsor
Evidence Based Cataract Study Group
Responsible party
Peng ZHOU (Doctor, Evidence Based Cataract Study Group) — Principal investigator
First posted
Jul 28, 2022
Start date
Aug 1, 2022 (estimated)
Primary completion
Aug 31, 2023 (estimated)
Completion
Aug 31, 2023 (estimated)
Last update
Jul 28, 2022

Study contacts

Peng Zhou, M.D.
Contact
drzhoupeng@gmail.com
17898805125

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion